Moderna (NASDAQ:MRNA) Postpones Plans of Vaccine Plant in Kenya
Market News

Moderna (NASDAQ:MRNA) Postpones Plans of Vaccine Plant in Kenya

Story Highlights

Moderna has postponed its plans of setting up a vaccine plant in Kenya.

Moderna (NASDAQ:MRNA) has postponed its plans to set up a vaccine manufacturing plant in Kenya, according to a Financial Times report. The biotech major had entered into a deal with the Kenyan government last year and intended to invest around $200 million in a facility that would produce up to 500 million vaccine shots a year.

Moreover, the Kenyan government gave Moderna several tax breaks and allowed it to more than halve its initial investment of $500 million.

Moderna confirmed to the Financial Times that it had paused the construction of a vaccine plant in Kenya. This decision was prompted by decreasing sales of its COVID-19 vaccine in Africa after the pandemic. As a result, it did not consider the investment in a plant in Kenya as “viable.”

The report cited analysts’ estimates, projecting MRNA to generate total COVID-19 vaccine sales of $3.9 billion this year. This marks a steep decline of 79% from its peak vaccine sales of $18.4 billion in 2022.

What Is the Forecast for MRNA Stock?

Analysts remain cautiously optimistic about MRNA stock, with a Moderate Buy consensus rating based on nine Buys, six Holds, and two Sells. Over the past year, MRNA has declined by more than 30%, and the average MRNA price target of $134.56 implies an upside potential of 28.6% from current levels.


Price Change
S&P 500
Dow Jones
Nasdaq 100

Popular Articles